NCT04234022 2026-04-09
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
The Royal Wolverhampton Hospitals NHS Trust
Recruiting
Clinical Trials
6 trialsNCT06163040 2025-07-31
A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT04458831 2025-06-27
IONA-MM
Sanofi
Active not recruiting
NCT03288974 2025-04-15
Pomalyst PMS
Celgene
Completed
NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed
NCT02164955 2022-10-20
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
Celgene
Completed